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Purpose: To study genetic predispositions and differences between severe chronic
central serous chorioretinopathy (cCSC), nonsevere cCSC, and acute central serous
chorioretinopathy (aCSC).
Methods: One hundred seventy-three severe cCSC patients, 272 nonsevere cCSC
patients, 135 aCSC patients, and 1,385 control individuals were included. Eight single-
nucleotide polymorphisms were genotyped in the ARMS2 (rs10490924), CFH (rs800292,
rs1061170, rs1065489, rs1329428, rs2284664, rs3753394), and NR3C2 (rs2070951). Addi-
tionally, C4B gene copy numbers were analyzed.
Results: A significant association in 5 single-nucleotide polymorphisms in the CFH gene
could be reproduced among severe cCSC patients, including rs800292 (P = 0.0014; odds
ratio [OR] = 1.93; 95% confidence interval [CI] = 1.51–2.47), rs1065489 (P = 2.22 · 1024; OR
= 0.49; 95% CI = 0.34–0.72), rs1329428 (P = 0.001; OR = 1.89; 95% CI = 1.49–2.40),
rs2284664 (P = 1.21· 1024; OR = 1.65; 95% CI = 1.28–2.13), and rs3753394 (P = 6.10·
1024; OR = 0.61; 95% CI = 0.46–0.81). Carrying three C4B copies was protective for severe
cCSC (P = 0.001; OR = 0.29; 95% CI = 0.14–0.61). No significant differences in allele
frequencies could be found among the CSC phenotypes.
Conclusion: Acute CSC, nonsevere cCSC, and severe cCSC all showed a similar
association with the CFH and C4B genes, and the three phenotypes could not be distin-
guished based on the genetics. This shows that despite the differences in clinical pre-
sentation and severity, there is an overlap in the genetic predisposition of different CSC
phenotypes. Nongenetic factors may play a more important role in determining the clinical
course of CSC.
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Central serous chorioretinopathy (CSC) is a chorior-etinal disease, characterized by serous fluid accu-
mulation in the subretinal space, often affecting the
macula with subsequent visual impairment.1 The
underlying pathophysiology of CSC is not fully under-
stood. However, a congested, hyperpermeable, and
leaking choroid, together with a damaged and dys-
functional retinal pigment epithelium (RPE) are
thought to underlie the subretinal fluid (SRF) accumu-
lation in CSC.2
At least two different CSC phenotypes can be
distinguished: acute and chronic CSC. Acute CSC
(aCSC) is generally considered self-limiting with
a near-complete visual recovery, thus not requiring
treatment in most cases. In contrast, chronic CSC
(cCSC) often has persistent SRF with more extensive
atrophic RPE changes, in which treatment can be
beneficial.1 There is no consensus on the duration
threshold that distinguishes acute and chronic CSC,
but an arbitrary period of 4 to 6 months of duration
of active disease (SRF leakage) is often considered for
the definition of chronicity.1 Apart from chronic SRF
leakage, patients with cCSC may present with a wide
spectrum of retinal abnormalities. In mild cCSC cases,
there are limited areas of RPE atrophy, few RPE de-
tachments, and a circumscribed area of leakage.3 More
severe cCSC cases show widespread or multifocal (or
both) areas of RPE atrophy, more numerous RPE
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detachments, diffuse areas of leakage, and intraretinal
cystoid degeneration.4–6 Moreover, this spectrum of
severe cCSC was previously shown to have the worst
visual prognosis among all cCSC cases, even after
treatment and complete resolution of SRF.7 Therefore,
severe cCSC may be considered a distinct clinical sub-
group within the spectrum of CSC.
Recently, specific single-nucleotide polymorphisms
(SNPs) in the age-related maculopathy susceptibility 2
(ARMS2), the complement factor H (CFH), and the
nuclear receptor subfamily three Group C member 2
(NR3C2) genes were found to be associated with the
risk of cCSC.8–10 Genomic copy number variations in
the complement component 4 (C4B) gene were also
shown to be associated with cCSC.11 As aCSC, “non-
severe” cCSC, and “severe” cCSC appear substantially
distinct CSC subgroups with regard to clinical mani-
festation and prognosis (Figure 1), these different CSC
forms may also have different genetic risk profiles.
In the present study, we analyzed the association of
SNPs in the ARMS2, CFH, and NR3C2 genes, and
copy numbers of C4B gene, in a cohort of cCSC pa-
tients who showed a severe disease presentation based
on previously published disease characteristics.7 In
addition, we analyzed and compared the association
of the aforementioned risk SNPs between three Cau-
casian CSC subgroups, including aCSC, cCSC with-
out characteristics of severity, and cCSC patients with
severity characteristics.
Materials and Methods
In total, 173 white subjects with a severe cCSC
phenotype were included, originating from four ter-
tiary referral centers: 65 patients from the Department
of Ophthalmology of Leiden University Medical
Center (Leiden, the Netherlands), 67 patients from
the Radboud University Medical Center (Nijmegen,
the Netherlands), 24 patients from the Rotterdam Eye
Hospital (Rotterdam, the Netherlands), and 17 patients
from the University Eye Hospital of Cologne
(Cologne, Germany).
Patients were phenotyped by two experienced retina
specialists (S.Y. and C.J.F.B.). For phenotyping,
a complete ophthalmological examination was used,
including fundoscopy, optical coherence tomography,
fluorescein angiography (FA), and, when available,
indocyanine green angiography. White patients were
included in the severe group of cCSC when they had
a history of active disease for more than 6 months, in
combination with at least one of the following
abnormalities: 1) cumulative areas of larger than five
optic disk diameters of diffuse atrophic RPE alter-
ations visible on midphase FA, 2) at least 2 “hot spots”
of leakage on midphase FA, 3) an area of diffuse
fluorescein leakage larger than one disk diameter on
midphase FA, without an evident leaking focus, or 4)
presence of posterior cystoid retinal degeneration as-
sessed on optical coherence tomography.7,12 Subjects
were excluded when there was a suspicion of a (sec-
ondary) choroidal neovascularization, aneurysmal cho-
roidal vasculopathy, age-related macular degeneration,
multifocal choroiditis, retinal vascular occlusions, or
high myopia. The presumably steroid-induced CSC
cases (steroid use within 3 months before CSC diag-
nosis) were not excluded from analysis.
The cohort of severe cCSC was genetically com-
pared with a cohort of 272 white patients with
nonsevere cCSC, who had a history of persistent
disease but did not have any of the 4 previously
mentioned characteristics of severity. Additionally,
severe cCSC was compared with 135 white patients
with aCSC, defined as a combination of 1) docu-
mented serous SRF accumulation on optical coherence
tomography, 2) a single focal leakage point on FA,
and 3) atrophic RPE alterations limited to less than one
disk diameter in size. The control group included
white individuals enrolled in the European Genetic
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Fig. 1. Clinical features on
multimodal imaging in different
CSC phenotypes. The right eye
of a 34-year-old man with aCSC
is shown in A–D. In E–H, the
left eye of a 43-year-old male
patient with nonsevere cCSC is
shown. In I–L, the right eye of
a 61-year-old male patient with
severe cCSC is shown. Fluores-
cein angiography imaging re-
vealed a single “hot spot” of
leakage and no atrophic RPE
changes in the aCSC patient (A).
Fluorescein angiography in the
nonsevere cCSC showed a leak-
age spot and multifocal small
areas of RPE changes (E),
whereas in the severe cCSC case,
large and widespread RPE atro-
phy and diffuse leaking areas
were seen (I). On midphase in-
docyanine green angiography, in
the aCSC case, a small hyper-
fluorescent lesion was observed
at the site of the “hot spot” on
fluorescein angiography (C). In
contrast, indocyanine green
angiography in the severe and
nonsevere cCSC patients showed
more extensive multifocal hy-
perfluorescent changes (G and
K). Fundus autofluorescence
imaging showed a mix of gran-
ular hyperautofluorescent and
hypoautofluorescent changes,
which were most prominent in
the severe cCSC patient (B, F,
and J). Optical coherence
tomography scan at first pre-
sentation revealed a subretinal
serous fluid accumulation and
subretinal debris in all patients
(D, H, and L). Furthermore,
a typical irregular shallow RPE
detachment was present in the
severe cCSC case (L), which is
often observed in combination
with chronic SRF leakage.
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Database (EUGENDA; www.eugenda.org), in whom
no signs of macular disease were found on multimodal
imaging, and 176 subjects included in the blood bank
of the Radboud University Medical Center. Approval
for this study was obtained at the local institutional
review boards in all participating centers, and the
study adhered to the tenets of the Declaration of Hel-
sinki. Written informed consent was obtained from all
subjects before blood collection for genetic analysis.
Single-Nucleotide Polymorphism Genotyping
DNA was isolated from peripheral blood using
standard procedures. The most relevant genetic var-
iants to be analyzed were chosen based on findings in
earlier genetic studies in CSC and included the
following variants: ARMS2 (rs10490924), CFH
(rs800292, rs1061170, rs1065489, rs1329428,
rs2284664, rs3753394), and NR3C2 (rs2070951),
and copy number variations in the C4B gene.8–11
KASP assays (LGC Genomics, Berlin, Germany) were
used for SNP genotyping, as described previously and
according to manufacturer’s instructions. A 7900HT
Fast Real-Time PCR system (Applied Biosystems by
Life Technologies, Austin, TX) was used to read out
the genotyping data. Data analysis was performed with
SDS (version 2.4, Applied Biosystems). A TaqMan
genotyping assay (Hs07226350_cn; Applied Biosys-
tems, Thermo Fisher Scientific, Waltham, MA) with
RNaseP as a reference assay was used to measure C4B
gene copy numbers, as described previously.
Statistical Analysis
The allele frequency of the SNPs in severe cCSC
patients was compared with unaffected controls, non-
severe cCSC, or aCSC subjects using a two-sided
Pearson’s chi-square test (IBM SPSS Statistics, ver-
sion 22; SPSS, Inc, Chicago, IL). The C4B copy num-
bers distribution was compared with a two-sided
Fisher’s exact test. Additionally, a logistic model cor-
recting for gender was designed, and two copies of
C4B were set as a reference.11 P values of ,0.0056
were considered statistically significant after a Bonfer-
roni correction for multiple testing for 9 variants. Hap-
lotype analysis correcting for gender was performed to
assess the combined effect of the selected six variants
in CFH using R (R Core Team, v3.0.2) with the hap-
lo.stats package (v1.7.7). As a reference, the two most
frequent haplotypes were used in the haplo.glm com-
mand to determine odds ratios (ORs) for the haplo-
types with a frequency .5% and the aggregate of the
haplotypes with a frequency of ,5%.
Results
In the present study, we included 173 patients with
severe cCSC (mean age: 54 ± 10 years; 151 [87%]
males), 272 patients with nonsevere cCSC (mean
age: 51 ± 10 years; 216 [79%] males), and 135 patients
with aCSC (mean age: 47 ± 10 years; 92 [68%]
males). The demographic characteristics are summa-
rized in Table 1.
Association With Single-Nucleotide Polymorphisms
in the ARMS2, NR3C2, and CFH Genes
No significant association was found with the
rs10490924 variant in ARMS2 gene or with the
rs2070951 variant in the NR3C2 gene in the severe
cCSC group after correction for multiple testing (Table
2). Also, no difference was observed in allele frequen-
cies of these tested variants when comparing severe
cCSC with nonsevere cCSC or aCSC (Table 3). An
association could be found in six tested variants in the
CFH gene in the severe cCSC group (Table 2). Asso-
ciations of five CFH variants remained significant after
correction for multiple testing: rs800292 (P = 0.0014;
OR = 1.93; 95% confidence interval [CI] = 1.51 to
2.47), rs1065489 (P = 2.22 · 1024; OR = 0.49; 95%
CI = 0.34–0.72), rs1329428 (P = 0.001; OR = 1.89;
95% CI = 1.49–2.40), rs2284664 (P = 1.21· 1024; OR
= 1.65; 95% CI = 1.28–2.13), and rs3753394 (P =
6.10· 1024; OR = 0.61; 95% CI = 0.46–0.81). No
difference was observed when comparing allele fre-
quencies of the six tested variants in the CFH gene
between severe cCSC and either nonsevere cCSC or
aCSC (Table 3).











No. of subjects 173 272 135 826 250 1,385
No. of male subjects 151 (87%) 216 (79%) 92 (68%) 424 (51%) 198 (79%) 635 (46%)
Mean age ± SD (years) 54 ± 10 51 ± 10 47 ± 10 64 ± 12 51 ± 10 51 ± 10
ARMS2, age-related maculopathy susceptibility 2; CFH, complement factor H; C4B, complement component 4; NR3C2, nuclear
receptor subfamily 3 Group C member 2.
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Association With CFH Haplotypes
Five haplotypes in the CFH gene with a frequency
higher than 5% and an aggregate of the haplotypes
with a frequency lower than 5% were identified. When
using the most common haplotype (H1) as a reference
and correcting for gender, severe cCSC showed an
association with H2, H3, H4, H5, and the low fre-
quency aggregated haplotypes (Table 4). However,
only H2 remained significant after correction for mul-
tiple testing, which was risk carrying for severe cCSC
(P = 0.001; OR = 1.73; 95% CI = 1.24–2.41; Table 4).
Using the H2 haplotype as a reference, H1 and H3
were found to be associated with severe cCSC after
correction for multiple testing, carrying a protective
effect (P = 0.0013; OR = 0.58; 95% CI = 0.41–0.81
and P = 4.14 · 1026; OR = 0.30; 95% CI = 0.18–0.50,
respectively; Table 4). When comparing the haplotype
frequencies of severe cCSC to this frequencies in


















G/T 171 0.187 812 0.217 0.214 0.83 (0.62–1.11)
rs2070951
(NR3C2)
C/G 172 0.494 1,385 0.468 0.350 1.11 (0.89–1.39)
rs800292
(CFH)
G/A 172 0.372 798 0.235 0.0014* 1.93 (1.51–2.47)
rs1061170
(CFH)
T/C 172 0.282 803 0.353 0.012 0.72 (0.56–0.93)
rs1065489
(CFH)
G/T 172 0.096 794 0.177 2.22 · 1024* 0.49 (0.34–0.72)
rs1329428
(CFH)
C/T 171 0.588 787 0.429 0.0010* 1.89 (1.49–2.40)
rs2284664
(CFH)
C/T 171 0.316 805 0.219 1.21 · 1024* 1.65 (1.28–2.13)
rs3753394
(CFH)
C/T 171 0.202 800 0.293 6.10 · 1024* 0.61 (0.46–0.81)
*Two-sided P values , 0.00556 were considered significant after correction for multiple testing.
ARMS2, age-related maculopathy susceptibility 2; CFH, complement factor H; MAF, minor allele frequency; NR3C2, nuclear receptor
subfamily 3 Group C member 2.
Table 3. Comparison of Allele Frequencies in Severe cCSC Versus Nonsevere cCSC and aCSC
SNPs (Locus)

















171 0.187 243 0.193 132 0.174 0.821 0.96 (0.67–1.37) 0.683 1.09 (0.72–1.66)
rs2070951
(NR3C2)
172 0.494 269 0.520 132 0.538 0.447 0.90 (0.69–1.18) 0.216 0.82 (0.59–1.13)
rs800292
(CFH)
172 0.372 245 0.296 133 0.320 0.021 1.41 (1.05–1.89) 0.177 1.26 (0.90–1.77)
rs1061170
(CFH)
172 0.282 245 0.320 133 0.259 0.235 0.83 (0.62–1.13) 0.534 1.12 (0.78–1.61)
rs1065489
(CFH)
172 0.096 244 0.133 134 0.119 0.101 0.69 (0.44–1.08) 0.350 0.78 (0.47–1.31)
rs1329428
(CFH)
171 0.588 244 0.510 133 0.579 0.0275 1.37 (1.04–1.81) 0.828 1.04 (0.75–1.43)
rs2284664
(CFH)
171 0.316 244 0.275 134 0.287 0.199 1.22 (0.90–1.65) 0.448 1.14 (0.81–1.62)
rs3753394
(CFH)
171 0.202 242 0.273 131 0.263 0.0192 0.67 (0.48–0.94) 0.073 0.71 (0.48–1.0)
Two-sided P values , 0.00556 were considered significant after correction for multiple testing.
*Group 1: severe cCSC.
†Group 2: nonsevere cCSC.
‡Group 3: aCSC.
ARMS2, age-related maculopathy susceptibility 2; CFH, complement factor H; MAF, minor allele frequency; NR3C2, nuclear receptor
subfamily 3 Group C member 2.
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nonsevere cCSC and aCSC, no significant differences
were found after correction for multiple testing (see
Tables 1 and 2, Supplemental Digital Content 1,
http://links.lww.com/IAE/B132 and http://links.lww.
com/IAE/B133, respectively).
C4B Copy Number Determination
The distribution of C4B copy numbers was signifi-
cantly different in severe cCSC compared with controls
after correction for multiple testing (P = 0.0020) (see
Figure 1, Supplemental Digital Content 3, http://
links.lww.com/IAE/B134). A logistic regression model
showed that carrying three C4B copies was protective
for severe cCSC (P = 0.001; OR = 0.29; 95% CI = 0.
14–0.61) (Table 5). The distribution of C4B copy num-
bers was not significantly different between severe
cCSC, nonsevere cCSC, and aCSC groups (see Figure
1, Supplemental Digital Content 3, http://links.lww.
com/IAE/B134). In addition, the overall logistic regres-
sion model for effect size was not significant when
comparing severe cCSC with nonsevere cCSC (P = 0.
665) or when comparing severe cCSC with aCSC (P =
0.551) (see Tables 4 and 5, Supplemental Digital
Content 4, http://links.lww.com/IAE/B135 and http://
links.lww.com/IAE/B136, respectively).
Discussion
There is a wide variety in the clinical presentation of
CSC, ranging from aCSC to severe chronic
CSC,1,7,12–14 and it is unclear whether these subgroups
are different with regard to pathogenesis and genetic
background. In the present study, we analyzed specific
genetic risk factors in severe cCSC patients and com-
pared them with nonsevere cCSC and aCSC patients.
Our data showed that in patients with severe cCSC,
three variants (rs800292, rs1329428, and rs2284664)
in the CFH gene were significantly associated with an
increased risk of the disease, whereas two variants
(rs1065489 and rs3753394) were protective. Also,
having three copies of the C4B gene was protective
against severe cCSC. However, no differences were
identified between severe CSC, nonsevere CSC, and
aCSC phenotypes.
A comparison of the genetic associations in the
three phenotypic subgroups indicated similar risk and
protective profiles in the CFH gene variants, CFH
haplotypes, and C4B gene copy numbers. Interest-
ingly, although the groups were not significantly dif-
ferent, the genetic effect size, in terms of protective or
risk-conferring ORs, was systematically larger in the
severe cCSC subgroup compared with nonsevere
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comparing the genetic effect size of CFH variants
rs800292, rs1329428, and rs1065489 in severe cCSC
with cCSC patients in the literature.9 Severe cCSC
may therefore have a stronger genetic predisposition
than milder CSC subtypes. Our findings indicate that
there is a significant overlap in the known genetic risk
factors and therefore likely also pathophysiological
overlap between CSC subtypes, despite clinical
differences.
A role for the complement system, and the CFH
gene in particular, in the pathogenesis of CSC was
suggested previously based on genetic association
studies.8,9,11 Our present study confirms this associa-
tion in all three CSC phenotypic subtypes. The choroid
and choriocapillaris play a central role in the patho-
genesis of CSC; although complement activity is
abundant in choroidal tissue,15 complement system
dysregulation may be a key factor in CSC disease
mechanism. A range of variants in genes involved in
the complement system have also been identified in
age-related macular degeneration.16,17 In contrast to
age-related macular degeneration, no systemic com-
plement abnormalities were found in a relatively small
group of cCSC patients.18,19 Local complement sys-
tem effects may be more important in CSC, rather than
systemic complement system abnormalities. However,
larger studies on systemic complement differences in
cCSC patients are necessary.
Patients with CSC share certain clinical character-
istics with age-related macular degeneration, such as
macular fluid leakage and RPE abnormalities, as well
as possible complication of choroidal neovasculariza-
tion,20 but there are also clear differences such as an
earlier age at onset, an absence of drusen, the presence
of pachychoroid, and association with steroid use. The
CFH variants reported in this study seem to have
opposite effects in CSC compared with age-related
macular degeneration, which may point to a different
role of the complement system in the pathophysiology
of these diseases as suggested before.8 In our current
cohorts, we could not replicate the associations with
the ARMS2 gene and NR3C2 gene variants as demon-
strated previously.8,10 This lack of a significant asso-
ciation may be explained by the smaller sample size of
the subgroups.
In the present study, a possible role of other,
currently unknown, genetic variants cannot be
excluded. Other factors may have a more prominent
role than genetic factors in determining the course and
severity of the disease. Daruich et al21 suggested that
older age (.40 years), presence of high (.50 mm)
RPE detachments, and a thickened (.500 mm) cho-
roid are significantly correlated with a prolonged epi-
sode of aCSC. Long-term steroid use has been
suggested not only to increase the risk of CSC but also
to cause a more severe bilateral chronic disease with
multiple RPE leaking sites, more extended areas of
RPE atrophy, and even bullous retinal detach-
ments.22–24 Piccolino et al12 have shown that presence
of posterior cystoid retinal degeneration, which was
considered a sign of severity in our study, is specifi-
cally associated with steroid use, longer duration of
symptoms, and subretinal fibrin accumulation. Fur-
thermore, severe cCSC presentations were previously
described in pregnant women25 and among certain
ethnic groups.26 Our findings suggest that the profile
of known genetic risk SNPs between phenotypically
different CSC patients is similar, and therefore, it is
likely that other factors, such as described above,
determine disease course and outcome.
In conclusion, associations between CFH genetic
variants and C4B copy numbers and severe CSC were
demonstrated, but no marked genetic differences were
found between acute, nonsevere, and severe chronic
phenotypes of CSC in the tested variants. This study
indicates that different phenotypes of CSC may not
develop as a result of genetic predisposition, at least
among the currently known CSC-associated CFH var-
iants. Presumably, other nongenetic risk factors such
as environmental factors or currently unknown genetic
Table 5. Logistic Regression Model for C4B Load in Severe cCSC Patients
Overall Significance Model P = 0.007
Controls (n = 250) Severe cCSC (n = 164) P OR (95% CI)
Male sex 198 (79%) 143 (87%) 0.010 0.48 (0.27–0.84)
C4B copy number
0 6 (2.4%) 4 (2%) 0.781 0.83 (0.23–3.04)
1 55 (22%) 51 (31%) 0.225 1.33 (0.84–2.12)
2 142 (57%) 99 (60%) Base Base
3 44 (18%) 10 (6%) 0.001* 0.29 (0.14–0.61)
4 3 (1.2%) 0 0.999 NA
*P-values , 0.0055 were considered significant after correction for multiple testing.
C4B, complement component 4; NA, not annotated.
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variants may play a role in the clinical course of CSC.
Future genetic and clinical studies in larger cohorts
may provide important clues about the different risk
factors associated with CSC disease severity.
Key words: acute central serous chorioretinopathy,
ARMS2, chronic CSC, complement factor H, comple-
ment component 4, genetic association, NR3C2, severe
CSC.
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